Meet The Team
Founder & Managing Director
Necdet Gunsoy, MPH PhD
Necdet Gunsoy has over a decade of technical and leadership expertise in the pharmaceutical industry, specializing in health economics and outcomes research (HEOR), health technology assessment (HTA), indirect treatment comparisons (ITC), and real world evidence (RWE). He has a proven track record of developing reimbursement evidence and economic models for global markets, including key regions such as the UK, Germany, France, and Canada. Necdet's extensive leadership experience includes building and managing large technical teams, launch evidence strategy planning, preparation, and execution. His technical knowledge and strategic insights have made significant contributions to market access and pricing strategies in diverse therapeutic areas.
Consultant,
Evidence Synthesis and Health Economics
Nadine Younan, PhD
Nadine brings over a decade of experience in medical research, with a specialised focus on dementia. During this time, she developed strong capabilities in medical writing, publication development, and scientific communication.
Nadine later moved into the field of health technology assessment, where she has built a robust background in evidence synthesis and economic modelling. She now brings expertise in cost-effectiveness and budget-impact modelling, systematic literature reviews, and statistical analysis using Excel, R, and STATA.
Her strong mathematical mindset, combined with her determination, technical rigour, strategic insight, and excellent communication skills, positions her as an asset to the team.
Senior Analyst
Tanvi Rajput
Tanvi brings over seven years of experience across health economics, market access, and HTA submissions, with a background in pharmacy and an MSc in Health Economics from the University of York.
Her experience at Novartis, Sanofi, and UCB Pharma spans literature reviews, economic evaluations, value dossiers, and HTA submissions, with a particular focus on oncology and cardiovascular health. She combines scientific rigour with a deep understanding of evidence-based decision-making.
Her expertise also covers market access strategy, including value communications, competitor landscaping, and the analysis of emerging trends in health economics.
Consultant, Statistics
Robin Philip
Robin brings a background in applied statistics and computer science. He has worked as a statistician across the UK and Australia in academia, government, and CRO environments, contributing to national audits and clinical research.
In the UK, he has over five years of experience designing and analysing real-world datasets, developing Shiny applications, and leading digital health studies in RWE.
Robin’s modelling experience includes meta and network meta-Analysis (NMA), survival analysis, and machine-learning models, including building neural networks from the ground up. His programming skills span R, Python, SAS, JavaScript, and Excel.
Senior Lead
Susie Huntington, PhD
Susie brings two decades of experience spanning consultancy, epidemiology, health economics, and health surveillance. Following national HIV and STI surveillance work in the UK and Spain and a PhD in Epidemiology at UCL, she has built an extensive career in HEOR consultancy, leading projects in cancer screening, respiratory medicine, and diagnostics. Her breadth of experience across academic, public health, and commercial settings makes her a valuable asset to the team.
.png)
Senior Analyst
Jiumei Gao
Jiumei brings over two years of healthcare consultancy experience, specializing in market access strategies and health economics across global markets. Her fluency in both Chinese and Japanese makes her perfectly positioned to navigate APAC marketplaces. Before entering consultancy, she worked in the non-profit sector, where she was committed to enhancing patient outcomes.
Analyst
Chaitanyamayee Kalakota
Chaitanyamayee brings a unique combination of expertise in pharmaceutical sciences and health economics. After completing her Bachelor’s in pharmaceutical science and a master's in pharmacy practice, she discovered her passion for health economics and went on to earn an MSc in Health Economics from the University of York. Her dissertation, “Producing robust estimates of cost-effectiveness in the presence of data gaps: assessment of NICE HST appraisals” explored the rare diseases where she conducted a targeted review of HST appraisals and developed an early cost-effectiveness model to address the uncertainty where data limitations are common.
We deliver streamlined solutions to enable patients faster access to innovative medicines
ACCESS STRATEGY.
EVIDENCE GENERATION.
HEALTH ECONOMICS.
HTA, REIMBURSEMENT & PRICING.